Sign in
Taking people in United StatesPhase 3

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Key facts

Who runs it
Yale University
Where
Camden, Oakland, Portland, Salt Lake City, and San Leandro, United StatesSee the 5 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
360 people, planned
Started
6 Dec 2024
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Buprenorphine
Record updated
28 May 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • All patients enrolled into the study must:
  • Be 18-65 years of age
  • Be treated in the ED during study screening hours
  • Meet DSM-5 diagnostic criteria for moderate to severe OUD
  • Have a Clinical Opiate Withdrawal Scale (COWS) score of ≥8 at enrollment (including 2 objective signs of withdrawal at enrollment)
  • Have a urine toxicology test that is positive for opioids
  • Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study

Who cannot take part

  • Have prior enrollment in the current study
  • Receiving MOUD treatment within the past 7 days
  • Be a participant in any other clinical trial in which medications are being delivered or the use of an investigational drug or device within the last 30 days
  • Have a medical or psychiatric condition that requires hospitalization at the time of index ED visit
  • Have a known hypersensitivity reaction to buprenorphine/naloxone
  • Have a physical exam or reported history consistent with severe liver failure
  • All patients enrolled into the study must not:
  • Be actively suicidal or severely cognitively impaired precluding informed consent
  • Require ongoing prescription for opioid analgesics
  • Have a positive urine test for methadone and reported use in the past 72 hours
  • Be a prisoner or in police custody at the time of index ED visit
  • Be unwilling to follow study procedures (e.g., unwilling to provide permission to contact referral provider/program or unavailable for the follow-up assessments)
  • Be pregnant as determined by human gonadotropin (hCG) testing at the index ED visit
  • Have a respiratory rate <8 or oxygen saturation <93%

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Cooper University HospitalCamden, United StatesContact: Christopher Jones, MDTaking people
  • Highland HospitalOakland, United StatesContact: Andrew Herring, MDTaking people
  • Maine Medical CenterPortland, United StatesContact: Tania Strout, PhD, RN, MSTaking people
  • University of Utah HospitalSalt Lake City, United StatesContact: Alyrene Dorey, MDTaking people
  • San Leandro HospitalSan Leandro, United StatesContact: Erik S Anderson, MDTaking people

About the trial

What the trial wants to find out

This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.

The 2 groups in the trial

  • High Dose SL-BUPTreatment being tested

    Participants will receive three 5.7 mg Zubsolv pills; all will be active medication.

    Treatment: Buprenorphine

  • Standard SL-BUPExisting treatment, for comparison

    Participants will receive three pills; one 5.7 mg Zubsolv pill with active medication and two placebo pills.

    Treatment: Buprenorphine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ED-Initiated Standard Versus High Dose Buprenorphine Induction
Fit questions
Built from NCT06494904, who can take part
Publications
Record updated
28 May 2026